TRACON Pharmaceuticals Inc (TCON)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading TRACON Pharmaceuticals Inc chart...

About the Company

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Exchange

NASDAQ

Website

traconpharma.com

$20M

Total Revenue

27

Employees

$17M

Market Capitalization

-1.02

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TCON News

TRACON Pharmaceuticals Inc TCON

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

TRACON Pharmaceuticals Inc T051

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

13d ago, source:

Research and development expenses for the fourth quarter of 2023 were $1.5 million, compared to $3.9 million for the fourth quarter of 2022. The decrease was primarily related to enrollment into only ...

Buy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical Trials

11d ago, source:

Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report) yesterday and set a price ...

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript

11d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call March 5, 2024 TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, ...

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript

11d ago, source: Insider Monkey

TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.03. TCON isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

TRACON Pharmaceuticals Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript

13d ago, source: Seeking Alpha

Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2023 Earnings Conference Call. [Operator Instructions] During today's call, we will be making ...

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript

11d ago, source: Insider Monkey

And to make clear what that potentially can mean to TRACON, if it’s a Phase I study and, for example, we can do a 30-patient Phase I study at $3 million and we know a CRO will charge typically $ ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...